Abstract
Efficacy of antiepileptic drugs is usually given in randomized, placebo-controlled trials as seizure-reduction rates and in rates of frequency of seizure-free patients. All side-effects have to be documented in these trials before new drugs come to the market. These data are not sufficient to give the potency of an antiepileptic drug in detail. Long-term retention rate gives us a better tool for measuring efficacy and side effects of patients on long-term antiepileptic drug treatment. In this meta analysis all papers from the Pubmed and Cochrane Library databanks, in which long-term retention rates of antiepileptic drugs were given as one of the key words, were analyzed. Controlled studies with long-term retention rates from at least six months were included.
Zusammenfassung
Die Beurteilung von antiepileptischer Medikation erfolgt in den randomisierten, Placebo-kontrollierten Zulassungsstudien meist in Form von Anfallsreduktionsquoten, zusätzlich wird die Häufigkeit von anfallsfreien Patienten angegeben und alle berichteten unerwünschten Wirkungen. Wirksamkeit und Nebenwirksamkeit werden so erfasst, wenn auch unvollständig. Ein Maß, das verschiedene Aspekte der Potenz einer antiepileptischen Substanz ausdrücken kann, ist das der Langzeitretention, in das sowohl Verträglichkeit als auch Wirksamkeit, wie auch Aspekte von Lebensqualität mit eingehen. Anhand der Datenbanken Pubmed und der Cochrane Library wird eine Analyse aller der Arbeiten vorgenommen, die Langzeitretention bei Antiepileptika als Maß berücksichtigten. Dabei sollte die Beobachtungszeit mindestens 6 Monate betragen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Arroyo Dodson DE, Privitera MD et al (2005) Randomized dose-controlled study of topiramate as firstline therapy in epilepsy. Acta Neurol Scand 112:214–222
Beghi E, Gatti E, Tonini C et al (2003) Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 57(1):1–13
Bill PA, Vigonius U, Pohlmann H et al (1997) A double-blind controlled clinical trial of oxcarbazepin versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 27:195–204
Bootsma HP, Coolen F, Aldenkamp AP et al (2004) Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 5:380–387
Brodie MJ, Chadwick DW, Anhut H et al (2002) Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 43:993–1000
Brodie MJ, Overstall PW, Giorgi L et al (1999) Multicenter, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 37:81–87
Brodie MJ, Richens A, Yuen AWC (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345:476–479
Chadwick D, Anhut H, Greiner MJ et al (1998) A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 51:1282–1288
Christe W, Kramer G, Vigonius U et al (1997) A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 26:451–460
Cocito L, Mani M, Loeb C (1994) Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res 19:123–127
Dam M, Ekberg R, Løyning Y, Waltimo O, Jakobsen K (1989) A doubleblind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3:70–76
Depondt J, Yuen AW, Bell GS, Mitchel T, Koepp MJ, Duncan JS, Sander JW (2006) The long term retention of levetiracetam in a large cohort of patients with epilepsy. Neurol Neurosurg Psychiatry 77:101–103
Guerrero MM, Vigonius U, Pohlmann H et al (1997) A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 27:205–213
Kluger G et al (2005) Retentionsraten neuer Antiepileptika bei Kindern. In: Aksu F (Hrsg) Aktuelle Neuropädiatrie. Novartis Verlag, pp 301–304
Krakow K, Walker M, Otoul C, Sander JW (2001) Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56:1772–1774
Lhatoo SD, Wong IC, Polizzi G, Sander JW (2000) Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41:1592–1596
Lhatoo SD, Wong IC, Sander JW (2000) Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 41:338–341
Marson AG, Williamson PR, Clough H et al (2002) Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 43:505–513
Mattson RH, Cramer JA, Mc Cutchen B et al (1985) Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary generalized tonic-cloncic epileptic seizures. NEJM 313:145–151
Mattson RH, Cramer JA, Collins JF (1992) A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalised tonic clonic seizures in adult. N Engl J Med 327:765–771
Montenegro MA, Cendes F, Noronha AL et al (2001) Efficacy of Clobazam as Add-On Therapy in Patients with Refractory Partial Epilepsy. Epilepsia 42 (4):539–542
Nicolson A, Appleton RE, Chadwick DW, Smith DF (2004) The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 75:75–79
Nieto-Barrera M, Brozmanova M, Capovilla G et al (2001) A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 46:145–155
Privitera MD, Brodie MJ, Mattson RH et al (2003) Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 107:165–175
Rainesalo S, Peltola J, Auvinen A, Keanen T (2005) Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics. Seizure 14(1):72–74
Reunanen M, Dam M, Yuen AW (1996) A randomised open multicenter comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 23:149–155
Rowan AR, Ramsyay AE Collin JF et al (1999) New onset geriatric epilepsy: A randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64:1868 –1873
Sander JW, Trevisol-Bittencourt PC, Hart YM, Patsalos PN, Shorvon SD (1990) The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 7:226–229
Sivenius J, Ylinen A, Kalviainen R, Riekkinen PJ Sr (1994) Longterm study with gabapentin in patients with drug-resistant epileptic seizures. Arch Neurol 51:1047–1050.
Steiner TJ, Dellaportas CI, Findley LJ et al (1999) Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 40:601–607
Taylor S, Tudur Smith C, Williamson PR, Marson AG (2001) Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 4:CD002217
Tudur Smith C, Marson AG, Clough HE, Williamson PR (2002) Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2:CD001911
Tudur Smith C, Marson AG, Williamson PR (2001) Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 4:CD0017690
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mayer, T. Retentionsraten bei kontrollierten Antiepileptika-Studien. Z. Epileptol. 21, 6–16 (2008). https://doi.org/10.1007/s10309-008-0292-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10309-008-0292-2